Patents Assigned to Mitsubishi Tanabe Pharma Corporation
  • Publication number: 20210145798
    Abstract: A method for treating amyotrophic lateral sclerosis includes administering an effective amount of 3-methyl-1-phenyl-2-pyrazolin-5-one or a physiologically acceptable salt thereof to a patient who is in need thereof and meets two or more features selected from a group of identified features.
    Type: Application
    Filed: October 4, 2018
    Publication date: May 20, 2021
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Charlotte MERRILL, Wendy AGNESE, Nazem ATASSI, Tara GRABOWSKY, Takeshi SAKATA
  • Patent number: 11008388
    Abstract: The present invention aims to obtain an anti-repulsive guidance molecule a (RGMa) antibody having a high binding activity and few side effects which can be used as a medicine for preventing, treating, or preventing the relapse of neurological or immunological diseases. The problem is solved by providing an isolated RGMa binding protein which does not inhibit binding between RGMa and neogenin but neutralizes the neurite outgrowth inhibiting activity of RGMa, preferably by providing an anti-RGMa antibody which has complementarity determining regions having amino acid sequences of SEQ ID NOS: 30-35 or SEQ ID NOS: 36-40 in Sequence Listing, and SFG.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: May 18, 2021
    Assignees: MITSUBISHI TANABE PHARMA CORPORATION, OSAKA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY
    Inventors: Motonori Hashimoto, Toshihide Yamashita
  • Patent number: 11007172
    Abstract: The present invention provides an agent or pharmaceutical composition for eliminating senescent cells, comprising an SGLT2 inhibitor.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: May 18, 2021
    Assignees: NIIGATA UNIVERSITY, MITSUBISHI TANABE PHARMA CORPORATION
    Inventor: Tohru Minamino
  • Patent number: 10987341
    Abstract: An edaravone suspension for human oral administration includes edaravone particles, a dispersant, and water.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: April 27, 2021
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Tetsuo Hayama, Tomohiro Takahashi, Tomoyuki Omura, Kouji Hayashi, Munetomo Matsuda, Tadashi Miyazawa
  • Patent number: 10961269
    Abstract: A method for preparing a compound represented by general formula I: or a salt thereof includes a step of reacting a compound represented by formula II: with a reducing agent to cleave an oxazolidine ring fused to a cycle A?. The reducing agent includes at least one of phosphines, metal hydrides, or transition metal catalysts in the presence of hydrogen gas.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: March 30, 2021
    Assignees: MITSUBISHI TANABE PHARMA CORPORATION, OSAKA UNIVERSITY
    Inventors: Satoshi Obika, Eiji Kawanishi, Hiroaki Sawamoto, Shuhei Yamakoshi, Yuuki Aral, Shinji Kumagai
  • Publication number: 20210003544
    Abstract: This method of analyzing the phenylhydrazine content in a 3-methyl-1-phenyl-2-pyrazolin-5-one bulk drug involves: obtaining a first measured value by measuring the phenylhydrazine content of a standard solution that contains phenylhydrazine or a salt thereof, a first acidic water and a first water-soluble organic solvent, and that exhibits a phenylhydrazine concentration of 0.01 ?g/mL to 10 ?g/mL; obtaining a second measured value by measuring the phenylhydrazine content in a sample solution that contains a 3-methyl-1-phenyl-2-pyrazolin-5-one bulk drug, a second acidic water and a second water-soluble organic solvent; and detecting the phenylhydrazine content in the 3-methyl-1-phenyl-2-pyrazolin-5-one bulk drug on the basis of the first measured value and the second measured value.
    Type: Application
    Filed: February 27, 2019
    Publication date: January 7, 2021
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Takeshi WAKASUGI, Aya SANO
  • Publication number: 20200383968
    Abstract: The present disclosure is directed to compositions comprising as an active ingredient, a lower dose of 4-({(1-cyclopropy-lisoquinolm-3-yl)[4-(trifluoromethoxy)benzyl]amino}sulfonyl)benzoic acid or a pharmaceutically acceptable salt thereof for treating or preventing vasomotor symptoms in a subject, and methods which comprises administering the said compound or the pharmaceutically acceptable salt thereof at a lower dose, respectively.
    Type: Application
    Filed: December 18, 2018
    Publication date: December 10, 2020
    Applicant: Mitsubishi Tanabe Pharma Corporation
    Inventor: Joseph M. PALUMBO
  • Patent number: 10793582
    Abstract: Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. A compound represented by the formula (I) or a pharmacologically acceptable salt thereof. wherein each symbol is as defined in the DESCRIPTION.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: October 6, 2020
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Masahiro Okuyama, Kenji Fukunaga, Kenji Usui, Norimitsu Hayashi, Daisuke Iijima, Hideki Horiuchi, Nobuaki Fujimoto
  • Publication number: 20200289492
    Abstract: The present invention provides a drug for treating cocaine addiction or preventing the relapse of the same. Specifically, the present invention provides a drug for treating cocaine addiction or preventing the relapse of the same containing (R)-2-{3-[1-(5-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 27, 2017
    Publication date: September 17, 2020
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventor: Koji TESHIMA
  • Publication number: 20200268712
    Abstract: An edaravone suspension for human oral administration includes edaravone particles, a dispersant, and water.
    Type: Application
    Filed: May 12, 2020
    Publication date: August 27, 2020
    Applicant: Mitsubishi Tanabe Pharma Corporation
    Inventors: Tetsuo Hayama, Tomohiro Takahashi, Tomoyuki Omura, Kouji Hayashi, Munetomo Matsuda, Tadashi Miyazawa
  • Patent number: 10752575
    Abstract: The present invention relates to a production method of 4-alkoxy-3-trifluoromethylbenzyl alcohol at a high conversion ratio, which can strictly suppress production of a byproduct by using DIBAL as a reducing agent.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: August 25, 2020
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Makoto Kawano, Takashi Naka, Mitsuharu Nakamura, Hisao Takayanagi
  • Publication number: 20200239440
    Abstract: The present invention provides: a methyl 1-{2-[(3S,4R)-1-[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl) pyrrolidine-3-carbonyl]-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl) phenyl}piperidine-4-carboxylate 1/2 ethane-1,2-disulfonic acid which is represented by formula (1) and is excellent in crystallinity; and a method for producing the same; and a production intermediate thereof; and a production method using this compound.
    Type: Application
    Filed: September 28, 2018
    Publication date: July 30, 2020
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Joji TSURUMOTO, Kenji MOROKUMA
  • Patent number: 10717731
    Abstract: A compound represented by general formula [I] wherein X represents N or the like, Y represents CH or the like; RA represents a cycloalkyl group which may be substituted or the like, R1 represents an alkyl group or the like, R2 represents an alkyl group which may be substituted or the like, R3 represents a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof has an inhibitory activity on aldosterone synthetase, and is useful as a prophylactic and/or therapeutic agent for various diseases or symptoms associated with aldosterone.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: July 21, 2020
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Ryo Sakakibara, Hideki Ushirogochi, Wataru Sasaki, Yuichi Onda, Minami Yamaguchi, Fumihiko Akahoshi
  • Publication number: 20200024254
    Abstract: The present invention provides a process for preparing a compound represented by formula (VII), which comprises reacting a compound represented by formula (VI) with a malonic acid derivative in the presence of a base and an asymmetric catalyst in a two layer solvent system of hydrophobic solvent and water.
    Type: Application
    Filed: January 30, 2018
    Publication date: January 23, 2020
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Takao TESHIMA, Takafumi YAMAGAMI, Tetsuo YAMAGUCHI, Junki ANDO
  • Patent number: 10487072
    Abstract: The present invention relates to a novel imidazole compound or a pharmaceutically acceptable salt thereof having a melanocortin receptor agonistic activity, and medical use thereof. The present invention relates to an imidazole compound represented by general formula [I] [wherein: Ring A represents an optionally substituted aryl group or the like; R1 represents a hydrogen atom, an optionally substituted alkyl group, or the like; R2 represents a hydrogen atom, a halogen atom, or the like; and R3 represents an optionally substituted alkyl group] or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: November 26, 2019
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Atsushi Sato, Ritsuo Imashiro, Hidekazu Tsujishima, Kouichi Tanimoto, Yasuo Yamamoto, Tetsu Nakane, Chihiro Toshikawa
  • Publication number: 20190345454
    Abstract: A method of producing a rotavirus-like particle (RLP) in a plant is provided. The method comprises expressing within a host or host cell for example a plant, portion of a plant or plant cell one or more nucleic acid comprising one or more regulatory region operatively linked to a first, second and third nucleotide sequence, the regulatory region active in the host or host cell. The first nucleotide sequence encoding a first rotavirus protein, the second nucleotide sequence encoding a second rotavirus protein and the third nucleotide sequence encoding a third rotavirus protein. The first, second and third encode rotavirus protein NSP4 and VP2 or VP6 and VP4 or VP7. The host or host cell is incubated under conditions that permit the expression of the nucleic acids, so that NSP4 and either VP2 of VP6 and VP4 or VP7 are expressed, thereby producing the RLP. Hosts comprising the RLP, compositions comprising the RLP and method for using the composition are also provided.
    Type: Application
    Filed: March 29, 2019
    Publication date: November 14, 2019
    Applicants: MEDICAGO, INC, MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Pierre-Olivier LAVOIE, Marc-Andre D'AOUST
  • Patent number: 10407408
    Abstract: Provided is a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION. The compound has a selective MMP-9 production suppressive action, and is useful as a drug for the prophylaxis and/or treatment of autoimmune diseases such as rheumatoid arthritis and the like, inflammatory bowel diseases (ulcerative colitis, Crohn's disease) or osteoarthritis.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: September 10, 2019
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Seigo Ishibuchi, Kunio Saruta, Maiko Hamada, Nobuatsu Matoba, Tetsuji Matsudaira, Maki Seki, Akiko Tarao, Takashi Honjo, Shingo Ogata, Atsushi Kawata, Kenji Morokuma, Naoto Fujie, Yukio Aoyama
  • Publication number: 20190270799
    Abstract: The present invention aims to obtain an anti-repulsive guidance molecule a (RGMa) antibody having a high binding activity and few side effects which can be used as a medicine for preventing, treating, or preventing the relapse of neurological or immunological diseases. The problem is solved by providing an isolated RGMa binding protein which does not inhibit binding between RGMa and neogenin but neutralizes the neurite outgrowth inhibiting activity of RGMa, preferably by providing an anti-RGMa antibody which has complementarity determining regions having amino acid sequences of SEQ ID NOS: 30-35 or SEQ ID NOS: 36-40 in Sequence Listing, and SFG.
    Type: Application
    Filed: March 19, 2019
    Publication date: September 5, 2019
    Applicants: MITSUBISHI TANABE PHARMA CORPORATION, OSAKA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY
    Inventors: Motonori HASHIMOTO, Toshihide YAMASHITA
  • Publication number: 20190233438
    Abstract: Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. A compound represented by the formula (I) or a pharmacologically acceptable salt thereof. wherein each symbol is as defined in the DESCRIPTION.
    Type: Application
    Filed: October 21, 2016
    Publication date: August 1, 2019
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Masahiro OKUYAMA, Kenji FUKUNAGA, Kenji USUI, Norimitsu HAYASHI, Daisuke IIJIMA, Hideki HORIUCHI, Nobuaki FUJIMOTO
  • Publication number: 20190192482
    Abstract: The present invention provides an agent or pharmaceutical composition for eliminating senescent cells, comprising an SGLT2 inhibitor.
    Type: Application
    Filed: August 29, 2017
    Publication date: June 27, 2019
    Applicants: NIIGATA UNIVERSITY, MITSUBISHI TANABE PHARMA CORPORATION
    Inventor: Tohru MINAMINO